Allogeneic Stromal Vascular Fraction Accelerates Diabetic Wound Healing: A Cost-Effective Alternative to Adipose-Derived Stem Cells.
Demir H., Ozyazgan I., Gonen ZB., Yay AH., Mat OC., Gokdemir NS.
Animal Study on Diabetic Foot, Chronic Wound, published in Ann Plast Surg (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Ann Plast Surg (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41842714
- DOI
- 10.1097/SAP.0000000000004727
Abstract (original English)
Impaired wound healing in patients with diabetes mellitus is a major clinical problem resulting from chronic hyperglycemia, which disrupts immune function and prolongs inflammation. Cell-based therapies such as mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF) have shown promise in promoting tissue repair, yet comparative data between SVF and adipose-derived stem cells (ADSCs) remain limited. In this experimental study, a diabetic rat model was used to compare the effects of allogeneic SVF and allogeneic ADSCs on wound healing. Wound areas were measured on days 5, 10, and 14. Histological analyses, including assessments of reepithelialization, fibrosis, and epithelial tongue length, as well as cytokine level measurements, were performed to evaluate tissue regeneration and inflammation. Both SVF and ADSC groups demonstrated significantly smaller wound areas compared with controls at all time points ( P <0.05). On days 5, 10, and 14, the wound areas were 3.127±0.382, 0.833±0.360, and 0.552±0.185 cm 2 in the control group; 1.968±0.533, 0.543±0.165, and 0.347±0.144 cm 2 in the SVF group; and 2.242±0.565, 0.432±0.137, and 0.276±0.131 cm 2 in the ADSC group, respectively. Histological evaluation revealed enhanced reepithelialization and greater epithelial tongue length in both treatment groups. No significant differences were observed between SVF and ADSC groups. IL-1
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Efficacy of Stem Cell-Derived Exosomes in Promoting Diabetic Foot Ulcer Healing: A Meta-Analysis of Preclinical Animal Studies.
Meta-analysis on Diabetic Foot, Chronic Wound, published in J Diabetes Res (2026) — summary generated from the PubMed abstract.
- 2026
J Diabetes Res - Level AMeta-analysisEurope PMC
Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Meta-analysis with a reported sample of 2059 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 2059
Front Endocrinol (Lausanne) - Level AMeta-analysisEurope PMC
Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments
Meta-analysis on Diabetic Foot, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level AMeta-analysisPubMed
Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis.
Meta-analysis on Diabetic Foot, Chronic Wound, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
- 2025
Diabetol Metab Syndr6 citations - Level AMeta-analysisPubMed
A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.
Meta-analysis on Diabetic Foot, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis
Meta-analysis with a reported sample of 356 on Diabetic Foot, Chronic Wound, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
- n = 356
PeerJ1 citations